Matthew Kurian: The Era of oral novel SERDs in Breast Cancer is here
Matthew Kurian, Assistant professor of medicine at the University of Kentucky College of Medicine, shared a post on LinkedIn:
“The Era of oral novel SERDs in Breast Cancer is Here!
We are officially entering a transformative phase in breast cancer treatment, with oral SERDs demonstrating clinical benefit and potentially extending the lifespan of CDK4/6 inhibitors.
With elecestrant already FDA-approved, IMlunestrant (EMBER-3) presented at SABCS 2024, and the incoming SERENA-6, whose positive results will be presented at an upcoming meeting. But many others combinations being explored in phase 3 trials such as ELEVATE and pionERA!
This raises an important clinical question:
Should we start serial ESR1 mutation testing via liquid biopsy—given its superior detection rate—alongside routine imaging for monitoring and surveillance?
Could earlier intervention on an ESR1 mutation improve outcomes and potentially delay or prevent metastatic progression?
Looking forward to insights from colleagues and data from upcoming trials!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023